Introduction The present study aimed to describe characteristics of patients with type 2
diabetes (T2D) in UK primary care initiated on dapagliflozin, post-dapagliflozin changes in …

… For dapagliflozin, the increase in LDL cholesterol has been ∼2.9%, … dapagliflozin-induced
weight loss significantly contributes to the observed reductions in glycated haemoglobin (…

… , genital infections were more common in patients treated with dapagliflozin 5 mg/d and 10
… Hypoglycemia was also more frequent with dapagliflozin treatment, compared with placebo, …

… ) and reductions in glycated hemoglobin (HbA … dapagliflozin treatment in patients with T2D
and normal kidney function. This hematocrit elevation, associated with dapagliflozin treatment…

… glycated hemoglobin and to promote weight loss. Although the mechanism of action of
dapagliflozin … This study demonstrated that dapagliflozin treatment at 10 and 20 mg once daily (QD…

… On average, treatment with dapagliflozin results in improvement in glycated hemoglobin by
0.50%, fasting plasma glucose by 1 mmol/L, weight by 2 kg, body mass index by 1.1%, and …

… Treatment is based around monitoring glycated hemoglobin (HbA1c) as a measure of
glycemic control, and using a combination of lifestyle measures and medications to reduce blood …

… After 12 weeks of dapagliflozin treatment, glycated hemoglobin (HbA1c) and body mass
index were significantly decreased (P < 0.001) from 8.1 ± 1.3% to 7.5 ± 1.2% and from 28.1 ± …

… dapagliflozin as monotherapy or add-on therapy. Results from these studies demonstrated
that dapagliflozin to be noninferior to metformin in treatment … Additionally, dapagliflozin was …

… to week 12 in seated SBP and glycosylated hemoglobin (Hb A1c ); longitudinal repeated-…
, dapagliflozin-treated versus placebo-treated patients showed significant reductions in Hb A1c …